Recent advances in chemotherapy for advanced prostate cancer

被引：6

作者：

Olson K.B. ^{[1
]}

Pienta K.J. ^{[1
]}

机构：

[1] Urologic Oncology, University of Michigan Medical Center, 1500 East Medical Center Drive, 7303 CCGC, Ann Arbor, 48109, MI

来源：

Current Urology Reports | 2000年 / 1卷 / 1期

关键词：

Docetaxel; Estramustine; Prostate Cancer; Taxotere; Vinorelbine;

D O I：

10.1007/s11934-000-0035-z

中图分类号：

学科分类号：

摘要：

Recently, several important studies have validated prostatespecific antigen (PSA) as a reliable measure of response to chemotherapeutic treatment in advanced hormonerefractory prostate cancer. Furthermore, although chemotherapy in this setting has always been considered palliative, several analyses of recent clinical trials have demonstrated a significant association between declines in PSA values of 50% or more and prolonged survival. Mitoxantrone, in combination with prednisone, has been shown to provide significant palliation and improved quality of life. The use of combinations of chemotheraputic agents also seems to provide significantly superior objective and subjective responses compared with single-agent regimens. In particular, estramustine has been shown to synergize many of the agents used in prostate cancer treatment and has been demonstrated to provide significant palliation and decline in PSA levels in combination with vinblastine, vinorelbine, etoposide, paclitaxel, and docetaxel. The results of several important trials of the taxanes both as single agents and in combination with estramustine have been completed in the past year and have demonstrated that these agents are very effective in the treatment of hormone-refractory prostate cancer. © 2000, Current Science Inc.

引用

页码：48 / 56

页数：8

共 56 条

[21]

Moore M.J., Osoba D., Murphy K., Et al., Use of palliative end points to evaluate the effects of mitoxantrone and low-dose prednisone in patients with hormonally resistant prostate cancer, J Clin Oncol, 12, pp. 689-694, (1994)

[22]

Tannock I.F., Osoba D., Stockler M.R., Et al., Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative endpoints, J Clin Oncol, 14, pp. 1756-1764, (1996)

[23]

Osoba D., Tannock I.F., Ernst D.S., Neville A., Health-related quality of life in men with metastatic prostate cancer treated with prednisone alone or mitoxantrone and prednisone, J Clin Oncol, 17, pp. 1654-1663, (1999)

[24]

Kantoff P.W., Halabi S., Conaway M., Picus J., Et al., Hydrocortisone with or without mitoxantrone in men with hormonerefractory prostate cancer: results of the cancer and leukemia group B 9182 study, J Clin Oncol, 17, pp. 2506-2513, (1999)

[25]

Pienta K.J., Lehr J.E., Inhibition of prostate cancer growth by estramustine and etoposide: evidence for interaction at the nuclear matrix, J Urol, 143, pp. 1622-1625, (1993)

[26]

Hartley-Asp B., Kruse E., Nuclear protein matrix as a target for estramustine-induced cell death, Prostate, 9, pp. 387-395, (1986)

[27]

Wang L.G., Liu X.M., Kreis W., Et al., Androgen antagonistic effect of estramustine phosphate metabolites on wild-type and mutated androgen receptor, Biochem Pharmacol, 55, pp. 1427-1433, (1998)

[28]

Wang L.G., Liu X.M., Kreis W., Et al., Phosphorylation/dephosphorylation of androgen receptor as a determinant of androgen agonistic or antagonistic activity, Biochem Biophys Res Commun, 259, pp. 21-28, (1999)

[29]

Perry C.A., McTavish D., Estramustine phosphate sodium. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in prostate cancer, Drugs Aging, 7, pp. 149-174, (1995)

[30]

Kreis W., Budman D.R., Calabro A., Unique synergism or antagonism in combinations of chemotherapeutic second hormonal agents in human prostate cancer cell lines, Br J Urol, 79, pp. 196-202, (1997)

← 1 2 3 4 5 6 →